In the last trading session, 3.31 million Zomedica Corp. (AMEX:ZOM) shares changed hands as the company’s beta touched 0.99. With the company’s per share price at $0.17 changed hands at $0.01 or 7.90% during last session, the market valuation stood at $179.86M. ZOM’s last price was a discount, traded about -100.0% off its 52-week high of $0.34. The share price had its 52-week low at $0.15, which suggests the last value was 11.76% up since then. When we look at Zomedica Corp.’s average trading volume, we note the 10-day average is 3.58 million shares, with the 3-month average coming to 4.20 million.
Analysts gave the Zomedica Corp. (ZOM) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ZOM as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Zomedica Corp.’s EPS for the current quarter is expected to be $0.
Zomedica Corp. (AMEX:ZOM) trade information
Instantly ZOM was in green as seen at the end of in last trading. With action -3.34%, the performance over the past five days has been red. The jump to weekly highs of 0.1814 on Monday, 09/18/23 added 7.90% to the stock’s daily price. The company’s shares are showing year-to-date upside of 6.44%, with the 5-day performance at -3.34% in the red. However, in the 30-day time frame, Zomedica Corp. (AMEX:ZOM) is -10.10% down. Looking at the short shares, we see there were 70.32 million shares sold at short interest cover period of 17.39 days.
The consensus price target for the stock as assigned by Wall Street analysts is $0.44, meaning bulls need an upside of 61.36% from its current market value. According to analyst projections, ZOM’s forecast low is $0.44 with $0.44 as the target high. To hit the forecast high, the stock’s price needs a -158.82% plunge from its current level, while the stock would need to soar -158.82% for it to hit the projected low.
Zomedica Corp. (ZOM) estimates and forecasts
Data shows that the Zomedica Corp. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -8.68% over the past 6 months, a 50.00% in annual growth rate that is considerably higher than the industry average of 19.10%. Year-over-year growth is forecast to reach 61.60% up from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of $8.28 million. 1 analysts are of the opinion that Zomedica Corp.’s revenue for the quarter ending Dec 2023 will be $10.81 million. The estimates for the next quarter sales put growth at 75.60%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 28.40%. The 2023 estimates are for Zomedica Corp. earnings to increase by 9.70%.
Zomedica Corp. is expected to release its next quarterly earnings report in October.
Zomedica Corp. (AMEX:ZOM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.42% of Zomedica Corp. shares while 9.74% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 9.88%. There are 9.74% institutions holding the Zomedica Corp. stock share, with Vanguard Group Inc the top institutional holder. As of Jun 29, 2023, the company held 4.98% of the shares, roughly 48.81 million ZOM shares worth $9.76 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 1.17% or 11.51 million shares worth $2.3 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 33.69 million shares estimated at $6.74 million under it, the former controlled 3.44% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.36% of the shares, roughly 13.32 million shares worth around $2.66 million.